JPMorgan analyst Lisa Gill raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $180 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Balancing Strong Q1 Performance with Moderate Future Growth Outlook
- Quest Diagnostics: Strong Growth Potential and Resilience Amidst Economic Uncertainty
- Quest Diagnostics price target raised to $190 from $182 at Truist
- Quest Diagnostics price target raised to $194 from $191 at Baird
- Quest Diagnostics: Resilience and Growth Potential Amidst Macroeconomic Challenges